Srikanth Radhakrishnan - Dec 3, 2025 Form 3 Insider Report for Pulmonx Corp (LUNG)

Role
Chief Science &Techn. Officer
Signature
/s/ David Aaron Lehman, Attorney-in-Fact
Stock symbol
LUNG
Transactions as of
Dec 3, 2025
Transactions value $
$0
Form type
3
Date filed
12/10/2025, 06:59 PM
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Radhakrishnan Srikanth Chief Science &Techn. Officer C/O PULMONX CORPORATION, 700 CHESAPEAKE DRIVE, REDWOOD CITY /s/ David Aaron Lehman, Attorney-in-Fact 2025-12-10 0002098678

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding LUNG Common Stock 181K Dec 3, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding LUNG Employee Stock Option (right to buy) Dec 3, 2025 Common Stock 1.38K $1.40 Direct F2, F3
holding LUNG Employee Stock Option (right to buy) Dec 3, 2025 Common Stock 20.6K $2.20 Direct F2, F3
holding LUNG Employee Stock Option (right to buy) Dec 3, 2025 Common Stock 26.6K $43.40 Direct F2
holding LUNG Employee Stock Option (right to buy) Dec 3, 2025 Common Stock 43K $26.56 Direct F4
holding LUNG Employee Stock Option (right to buy) Dec 3, 2025 Common Stock 54K $11.48 Direct F5
holding LUNG Employee Stock Option (right to buy) Dec 3, 2025 Common Stock 31.6K $9.30 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 149,227 shares of the Issuer's common stock underlying Restricted Stock Units payable solely in common stock of the Issuer.
F2 Fully vested.
F3 The number of shares reported reflects the shares remaining outstanding as of December 3, 2025 under this option grant.
F4 The shares subject to this option vest in equal monthly installments over the four-year period from the grant date of March 1, 2022.
F5 The shares subject to this option vest in equal monthly installments over the four-year period from the grant date of March 1, 2023.
F6 The shares subject to this option vest in equal monthly installments over the four-year period from the grant date of March 1, 2024.